- Home
- WETH vs CVM Comparison
WETH vs CVM Comparison
Compare WETH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WETH | CVM |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 19.3M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WETH | CVM |
|---|---|---|
| Price | $1.50 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.0K | ★ 571.7K |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $45,136,818.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.62 | ★ N/A |
| Revenue Growth | 6.76 | ★ 65.45 |
| 52 Week Low | $0.78 | $0.89 |
| 52 Week High | $3.68 | $13.48 |
Technical Indicators
Market Signals| Indicator | WETH | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 31.10 |
| Support Level | $1.40 | N/A |
| Resistance Level | $1.85 | $4.84 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 19.59 | 23.73 |
Price Performance
Historical ComparisonAbout WETH Wetouch Technology Inc.
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.